AUROBINDO PHARMA LTD (AURO PHARMA)




Buy Around:	₹ 809-810
SL:	₹ 770
Target:	₹ 865-870
Upside:	7.50%
Horizon:	1 Month

VALUE PARAMETERS

Current Mkt.Price (Rs.)	799.80
Face Value (Rs.)	1.00
52 Week High/Low	891.50/582.00
M.Cap (Rs. in Cr.)	46801.86
EPS (Rs.)	31.15
P/E Ratio (times)	25.67
P/B Ratio (times)	9.08
Dividend Yield (%)	0.28
Stock Exchange	BSE

STOCK DATA

BSE Code	524804
NSE Symbol	AUROPHARMA
Reuters	ARBN.BO
Bloomberg	ARBP IN



SHAREHOLDING PATTERN (MARCH 2016)

The company is a beneficiary of faster approvals for its drugs in the US and all key plants of the company are compliant with the US Food and Drug Administration (USFDA) norms. Recently, it has received final approval from the USFDA to manufacture and market Fenofibrate tablets, used for the treatment of high level of cholesterol, in the American market and the product is expected to be launched in the first quarter of this fiscal. Almost 80% of company's net profit contribution are basically from US market and the management of the company expects that US sales to rise at a CAGR of 20% over next two years.

INVESTMENT ARGUMENTS

- Aurobindo Pharma's consolidated net profit rose 39.2% to Rs 534.95 crore on 9.2% growth in net sales to Rs 3432.08 crore in Q3 December 2015 over Q3 December 2014.
- It manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.
- It has a total of 259 ANDA approvals (222 final approvals including 11 from Aurolife Pharma LLC and 37 tentative approvals) from the US.
- Management has expected for EBITDA Margin in the range of 21 22%, while there is peak potential of EBITDA margin at 25% in coming years. Net debt decreased by US\$52m to US\$610m in Q3FY16. With increase in approvals and TADs (Target Action Date) in key drugs, there is strong visibility in earnings in FY17.
- Increase in volume of Aurolife's products, increase in government orders and higher sales of inject able drive impactful growth of the business of the company.

BUSINESS PROFILE

AURO PHARMA manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.



TECHNICAL TRENDS



We recommend a buy in the stock of AURO PHARMA from a short-term perspective. The stock is trading at its good support level with good fundamental records and is expected to move up from this level. It made a 52 week low Rs.582 and 52 week high of Rs 891.50. Buy around at 809-810 with a closing below stop loss of Rs.770 levels for the target of Rs.865-870.

Note:

• Follow Strict Stop Loss.

SMC Research Desk

SMC Research also available on Reuters

Moneywise. Be wise.	Corporate Office:	Mumbai Office:	Kolkata Office:
	11/6B, Shanti Chamber,	Dheeraj Sagar, 1st Floor,	18, Rabindra Sarani,
	Pusa Road, New Delhi - 110005	Opp. Goregaon sports club, link road	"Poddar Court", Gate No. 4,
	Tel: +91-11-30111000	Malad (West), Mumbai - 400064	4th Floor, Kolkata - 700001
	www.smcindiaonline.com	Tel: 91-22-67341600, Fax: 91-22-28805606	Tel: 91-33-39847000, Fax: 91-33-39847004

SMC Global Securities Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH100001849. SMC Global Securities Limited or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities Market.

SMC or its associates including its relatives/analyst do not hold any financial interest/beneficial ownership of more than 1% in the company covered by Analyst. SMC or its associates and relatives does not have any material conflict of interest. SMC or its associates/analyst has not received any compensation from the company covered by Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the company covered by analyst or third party in connection with the research report. The Analyst has not served as an officer, director or employee of company covered by Analyst and SMC has not been engaged in market making activity of the company covered by Analyst.

The views expressed are based solely on information available publicly available/internal data/ other reliable sources believed to be true

SMC does not represent/ provide any warranty express or implied to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision.

SMC Global Securities Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a further public offering of its equity shares and has filed the Draft Red Herring Prospectus with the Securities and Exchange Board of India ("SEBI") and the Stock Exchanges. The Draft Red Herring Prospectus is available on the website of SEBI at www.sebi.gov.in and on the websites of the Book Running Lead Manager i.e., ICICI Securities Limited at www.iccisecurities.com and the Co- Book Running Lead Manager i.e., Elara Capital (India) Private Limited at www.ealaracapital.com . Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section titled "Risk Factors" of the aforementioned offer document.

DISCLAMIER: This report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to you. It is only for private circulation and use. The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of the report. The report should not be reproduced or redistributed to any other person(s)in any form without prior written permission of the SMC.

The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions.

Please note that we and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance if this material; (a) from time to time, may have long or short positions in, and buy or sell the commodities thereof, mentioned here in or (b) be engaged in any other transaction involving such commodities and earn brokerage or other compensation or act as a market maker in the commodities discussed herein (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High court.

E-mail: researchfeedback@smcindiaonline.com